Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients with advanced NSCLC treated with nivolumab. Plasma o...

Full description

Bibliographic Details
Main Authors: Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
nivolumab
non-small cell lung cancer
plasma
pd-l1
pd-l2
granzyme b
interleukine-2
interferon-γ
microrna
biomarker
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1452581

Internet

http://dx.doi.org/10.1080/2162402X.2018.1452581

Similar Items